Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis
Background: To date, coronavirus disease 2019 (COVID-19) becomes increasingly fierce
due to the emergence of variants. Rapid herd immunity through vaccination is needed to …
due to the emergence of variants. Rapid herd immunity through vaccination is needed to …
COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence
Dermatologists diagnose and treat many immune-mediated inflammatory diseases (IMID).
Understanding the inherent immune dysregulation of these diseases as well as the …
Understanding the inherent immune dysregulation of these diseases as well as the …
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general …
V Furer, T Eviatar, D Zisman, H Peleg, D Paran… - Annals of the rheumatic …, 2021 - Elsevier
Introduction Vaccination represents a cornerstone in mastering the COVID-19 pandemic.
Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with …
Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with …
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician …
Objectives To describe the safety of vaccines against SARS-CoV-2 in people with
inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD). Methods …
inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD). Methods …
Disease flare and reactogenicity in patients with rheumatic and musculoskeletal diseases following two‐dose SARS–CoV‐2 messenger RNA vaccination
Objective To evaluate disease flare and postvaccination reactions (reactogenicity) in
patients with rheumatic and musculoskeletal diseases (RMDs) following 2‐dose SARS–CoV …
patients with rheumatic and musculoskeletal diseases (RMDs) following 2‐dose SARS–CoV …
Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform …
Objectives Perform a systematic literature review (SLR) on risk and prognosis of SARS-CoV-
2 infection and vaccination against SARS-CoV-2 in patients with rheumatic and …
2 infection and vaccination against SARS-CoV-2 in patients with rheumatic and …
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV
This study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV (PWH) demonstrated
uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres after two …
uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres after two …
Adverse events after first COVID-19 vaccination in patients with autoimmune diseases
June 18, 2021 https://doi. org/10.1016/S2665-9913 (21) 00181-8 digital platforms has had
an adverse impact on diversity and participation from under-represented groups due to …
an adverse impact on diversity and participation from under-represented groups due to …
Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study
JA Esquivel-Valerio, CM Skinner-Taylor… - Rheumatology …, 2021 - Springer
Data regarding COVID-19 vaccine efficacy and adverse events (AE) in patients with
autoimmune and inflammatory rheumatic diseases (AIIRD) have been published recently …
autoimmune and inflammatory rheumatic diseases (AIIRD) have been published recently …
A systematic review on mucocutaneous presentations after COVID‐19 vaccination and expert recommendations about vaccination of important immune‐mediated …
With dermatologic side effects being fairly prevalent following vaccination against COVID‐
19, and the multitude of studies aiming to report and analyze these adverse events, the need …
19, and the multitude of studies aiming to report and analyze these adverse events, the need …